- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06503510
Il ruolo dei percorsi dell'interleuchina-13 sulla sensibilità al dolore e al prurito nei pazienti con dermatite atopica e nei volontari sani (IL-13)
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the interleukin-13 is involved in inflammation and itch in atopic dermatitis by increasing the neuronal sensitivity to pruritogens. However, the physiological mechanisms by which IL-13 increases the itch sensitivity are unclear. The aim of this project is to use, for the first time in humans, the monoclonal antibody Lebrikizumab that inhibits IL-13 with high affinity as a novel experimental tool to modulate the IL-13 pathway and evaluate its role in the transmission and processing of itch and pain.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Silvia Lo Vecchio
- Numero di telefono: 21397785
- Email: slv@hst.aau.dk
Luoghi di studio
-
-
Aalborg
-
Gistrup, Aalborg, Danimarca, 9260
- Reclutamento
- Aalborg University
-
Contatto:
- Silvia Lo Vecchio, PhD
- Numero di telefono: 21397785
- Email: slv@hst.aau.dk
-
Contatto:
- Botilla Markussen
- Numero di telefono: 20567502
- Email: bam@hst.aau.dk
-
Investigatore principale:
- Silvia Lo Vecchio, PhD
-
Sub-investigatore:
- Botilla Markussen
-
Gistrup, Aalborg, Danimarca, 9260
- Attivo, non reclutante
- CNAP
-
-
Denmark
-
Aalborg, Denmark, Danimarca, 9260
- Non ancora reclutamento
- Aalborg University
-
Contatto:
- Silvia Lo Vecchio
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy men and women
- 18-60 years
Exclusion Criteria:
- Pregnancy or lactation
- Drug addiction defined as any use of cannabis, opioids, or other drugs
- Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
- Moles, wounds, scars, or tattoos in the area to be treated or tested
- Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).
- Use of systemic and topical corticosteroids
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Acute or chronic pain
- Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
- Lack of ability to cooperate
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Lebrikizumab
The initial doses will be subcutaneous Lebrikizumab 500 mg (two 250 mg injections) at both week 0 (baseline) and week 2, followed by 250 mg administered subcutaneously at week 4. |
Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin. A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop. A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Superficial blood perfusion
Lasso di tempo: Baseline
|
Superficial blood perfusion (SBP) is measured by a Speckle contrast imager |
Baseline
|
|
Mechanically evoked itch (MEI)
Lasso di tempo: Baseline
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
Baseline
|
|
Measuring itch by computerized Visual Analog Scale Scoring
Lasso di tempo: 1 minute after every itch induction
|
The subjects will be asked to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable". |
1 minute after every itch induction
|
|
Measuring pain by computerized Visual Analog Scale Scoring
Lasso di tempo: 1 minute after every itch induction
|
The subjects will be asked to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable". |
1 minute after every itch induction
|
|
Superficial blood perfusion
Lasso di tempo: 10 minute after every itch induction
|
Superficial blood perfusion (SBP) is measured by a Speckle contrast imager |
10 minute after every itch induction
|
|
Wheal reaction
Lasso di tempo: 10 minute after every itch induction
|
Wheal reaction measurement will be conducted immediately after the removal of pruritogens by measuring the longest diameter with a ruler. |
10 minute after every itch induction
|
|
Average pruritis and pain numerical rating scale (NRS)
Lasso di tempo: Baseline
|
The subject will be asked to retrospectively rate the average and worst itch/pain on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)experience they had during the last 7 days. |
Baseline
|
|
Skin peak pain numerical rating scale (SPP-NRS)
Lasso di tempo: Baseline
|
According to the SPP-NRS, the subject will be asked about "worst skin pain" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain) |
Baseline
|
|
Peak pruritus numerical rating scale (PP-NRS)
Lasso di tempo: Baseline
|
The subject will be asked about the "worst itch" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no itch and 10 = worst imaginable itch) |
Baseline
|
|
Mechanically evoked itch (MEI)
Lasso di tempo: 10 minutes after every itch induction
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
10 minutes after every itch induction
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mechanical Pain Thresholds (MPT)
Lasso di tempo: Baseline
|
This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. |
Baseline
|
|
Mechanical Pain Sensitivity (MPS)
Lasso di tempo: Baseline
|
This test is conducted with the same pinprick set used to test the MPT. |
Baseline
|
|
Pressure Pain Thresholds (PPT)
Lasso di tempo: Baseline
|
Pressure will be applied by a handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) on to the supinator muscle on the left forearm. |
Baseline
|
|
Cold Detection Thresholds (CDT)
Lasso di tempo: Baseliene
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseliene
|
|
Warm Detection Thresholds (WDT)
Lasso di tempo: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testingdevice |
Baseline
|
|
Cold Pain Thresholds (CPT)
Lasso di tempo: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
|
Heat Pain Thresholds (HPT)
Lasso di tempo: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
|
Pain to Supra-threshold Heat Stimuli (STHS)
Lasso di tempo: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Manifestazioni cutanee
- Malattie della pelle
- Condizioni patologiche, segni e sintomi
- Malattie della pelle e del tessuto connettivo
- Segni e sintomi
- Prurito
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Azoli
- Fattori biologici
- Imidazoli
- Ammine
- Etilammine
- Autacoidi
- Mediatori di infiammazione
- Monoamine biogeniche
- Amine biogeniche
- Istamina
- bovine adrenal medulla 8-22
Altri numeri di identificazione dello studio
- N-20240029
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .